SCHEDULE: T. Rowe Price Boosts Generation Bio Stake to 8.6%

T. Rowe Price Associates, Inc. has reported an 8.6% beneficial ownership stake in Generation Bio Co. common stock as of September 30, 2025.

Summary

• T. Rowe Price Associates, Inc. holds a beneficial ownership of 576,789 shares of Generation Bio Co. common stock.
• This represents 8.6% of the total class of securities.
• T. Rowe Price Associates, Inc. has sole voting power over 552,291 shares and sole dispositive power over 576,789 shares.
• The filing is an Amendment No. 7 to a Schedule 13G, indicating an update to a previously reported position.
• T. Rowe Price Associates, Inc. is classified as an Investment Adviser (IA).

Sentiment

Score: 5

Explanation: The filing is a routine disclosure of beneficial ownership by an institutional investor, T. Rowe Price Associates, Inc., in Generation Bio Co. It provides factual data on the stake held but does not contain information that would directly indicate a positive or negative sentiment regarding the issuer's operational performance or future prospects. The significant stake (8.6%) by a reputable investment adviser could be interpreted as a positive signal by some investors, but the filing itself is neutral in tone and content.

Future Outlook

NA

Management Comments

• The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11.
• T. Rowe Price Associates, Inc. hereby declares and affirms that the filing of Schedule 13G shall not be construed as an admission that Price Associates is the beneficial owner of the securities referred to, which beneficial ownership is expressly denied.

Industry Context

This filing reflects a significant institutional investment in Generation Bio Co., a biotechnology company. Such disclosures are common for investment advisers managing large portfolios and provide transparency into major equity holdings within the biotech sector.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional investor's stake, which can influence market perception and liquidity.
• Company Management: Awareness of a major institutional holder, potentially impacting engagement strategies with large investors.

Key Dates

Keywords

Generation Bio Co, T. Rowe Price Associates, Schedule 13G, Beneficial Ownership, Common Stock, Investment Adviser, Institutional Investor, Equity Stake